Preventability of drug-related harms part iI: Proposed criteria, based on frameworks that classify adverse drug reactions

Drug Safety

Volumn 33, Issue 11, 2010, Pages 995-1002

  Aronson, Jeffrey K ^a   Ferner, Robin E ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adverse drug reactions; Pharmacovigilance

Indexed keywords

ABACAVIR; ATROPINE DERIVATIVE; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; CAFFEINE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DECARBOXYLASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; EYE DROPS; FEXOFENADINE; GENTAMICIN; HALOTHANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; INSULIN; LEVODOPA; MERCAPTOPURINE; MESNA; NEOSTIGMINE; PENICILLIN DERIVATIVE; PROPRANOLOL; TERFENADINE; TETRACYCLINE; TRYPTOPHAN; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA MYALGIA SYNDROME; FANCONI ANEMIA; HEART INFARCTION; HEMORRHAGIC CYSTITIS; HUMAN; PARKINSONISM; PENICILLIN ALLERGY; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROPHYLAXIS; RHABDOMYOLYSIS; SKIN CANCER; UNSPECIFIED SIDE EFFECT;

ACCIDENT PREVENTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOXICITY; HUMANS; MEDICATION ERRORS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; TIME FACTORS;

EID: 77957775831     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11538280-000000000-00000     Document Type: Article

References (27)

1. Olivier P, Caron J, Haramburu F, et al. Validation d'une echelle de mesure: exemple de l'echelle française d'evit-abilite des effets indesirables medicamenteux. Therapie 2005; 60 (1): 39-45
2. Ferner RE, Aronson JK. Preventability of drug-related harms-part I: a systematic review. Drug Saf 2010; 33 (11): 985-94
3. Ferner RE, Aronson JK. EIDOS: a mechanistic classifica-tion of adverse drug effects. Drug Saf 2010; 33 (1): 15-23
4. Howick J, Glasziou P, Aronson JK. Evidence-based me-chanistic reasoning. J R Soc Med. In press
5. Pichichero ME. A review of evidence supporting the Amer-ican Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115 (4): 1048-57
6. Simat TJ, Kleeberg KK, Muller B, et al. Synthesis, forma-tion, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 1999; 467: 469-80
7. Chen C. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D 2007; 8 (5): 301-14
8. Montoliu J, Carrera M, Darnell A, et al. Lactic acidosis and Fanconi's syndrome due to degraded tetracycline. Br Med J (Clin Res Ed) 1981; 283 (6306): 1576-7
9. Flacke W. Treatment of myasthenia gravis. N Engl J Med 1973; 288 (1): 27-31
10. Shaw IC, Rose JWP. Infusion of ifosphamide plus mesna. Lancet 1984; I (8390): 1353-4
11. Ben Abraham R, Adnet P, Glauber V, et al. Malignant hyperthermia. Postgrad Med J 1998; 74 (867): 11-7
12. Marsh S, Van Booven DJ. The increasing complexity of mercaptopurine pharmacogenomics. Clin Pharmacol Ther 2009; 85 (2): 139-41
13. Phillips EJ, Mallal SA. HLA and drug-induced toxicity. Curr Opin Mol Ther 2009; 11 (3): 231-42
14. SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy: a genome-wide study. N Engl J Med 2008; 359 (8): 789-99
15. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332 (7551): 1177-81
16. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991; 164: 1180-5
17. Martin J, editor. British national formulary. No. 57. Section 4.7.3. Trigeminal neuralgia. London: BMJ Group and RPS Publications, 2009
18. Slome R. Withdrawal of propranolol and myocardial in-farction. Lancet 1973; I (7795): 156
19. iPledge: committed to pregnancy prevention [online]. Available from URL https://www.ipledgeprogram.com/PatientInformation.aspx [Accessed 2010 Jul 14].
20. Peto R. Influence of dose and duration of smoking on lung cancer rates. IARC Sci Publ 1986; (74): 23-33
21. Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ 1981; 282 (6268): 974-6
22. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28 (10): 851-70
23. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5
24. Bareggi SR, Tata MR, Guizzaro A, et al. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Int Clin Psychopharmacol 1994; 9 (1): 9-16
25. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326 (7404): 1419-23
26. Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv 2005; 65 (4): 525-7
27. Khoo SH, Bond J, Denning DW. Administering amphote-ricin B: a practical approach. J Antimicrob Chemother 1994; 33 (2): 203-13